Experimental study of sitagliptin on the delay or stop of the progress of type 2 nephropathy
10.13699/j.cnki.1001-6821.2016.01.015
- VernacularTitle:西格列汀延缓或阻止2型糖尿病肾病进展的实验研究
- Author:
Dong-Dong WANG
1
;
Tong WEI
;
Su-Mei HE
;
Guan-Ying ZHANG
;
Xiao CHEN
;
Qun-Li WEI
Author Information
1. 徐州医学院
- Keywords:
sitagliptin;
type 2 diabetic nephropathy;
Toll-like-recep-tor 2;
4/nuclear factor-κB pathway
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(1):45-47,54
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the derect action and part possible mechanism of sitagliptin ( SIT ) on the delay or stop of the progress of type 2 diabetic nephropathy (DN).Methods The rats were randomly divided into normal group ( NC group ) , diabetic nephropathy group ( DN group) and sitagliptin treatment group (SIT group).The type 2 diabetes mellitus rats were induced by a high fat diet and repeated low dose strep-tozocin injections.At the end of the 12th week in treatment, Masson stai-ning was used to observe the renal fibrosis .RT-PCR was used to detect the mRNA levels of Toll-like-receptor 2 (TLR2), TLR4, nuclear fac-tor-κB ( NF-κB ) .Immunohistochemical method was used to detect the content of TLR2 and TLR4.Western blotting was used to detect the content of NF-κB.Results Compared with NC group , the degree of renal fibrosis, and the expressions of TLR2, TLR4, NF -κB of DN group significantly increased ( P<0.01 ) .However , compared with DN group, the degree of renal fibrosis , and the expressions of TLR2, TLR4, NF-κB of SIT -treated rats significantly decreased ( P <0.05 ) . Conclusion SIT can prevent the renal fibrosis by down -regulating the expression of TLR2, TLR4/NF-κB pathway.
